How Ebola Vaccines Were Developed: From 1976 to Approved Immunisation
The story of Ebola vaccine development spans 40 years — from the virus's discovery in 1976 to the first approved vaccines in 2019–2020. This article traces the scientific journey, the pivotal trials, and what vaccines now exist.
Forty Years Without a Vaccine
Ebola was identified in 1976. The first approved vaccine did not reach patients until 2019. For four decades, a known, deadly, periodic disease had no licensed preventive tool. Understanding why — and how that changed — tells us something important about how the world prioritises global health threats.
Why Vaccine Development Was Slow: The Pre-2014 Era
”Neglected” Disease Dynamics
Before 2014, Ebola outbreaks were episodic, geographically limited, and relatively small (typically <400 cases). For pharmaceutical companies, this created an economic calculation problem:
- R&D costs: $1–3 billion for a typical vaccine
- Market size: Unpredictable, limited to outbreak responders and affected communities with little purchasing power
- Frequency of use: Irregular — potentially no cases for years, then sudden demand
Without military or government procurement guarantees, private investment in Ebola vaccine development was minimal.
Technical Challenges
Ebola vaccine development also presented scientific challenges:
- Work with live Ebola requires BSL-4 containment — the highest biosafety level, with only ~50 facilities worldwide
- Traditional approaches (killed-virus or live-attenuated vaccines) failed to induce sufficient immune responses in early research
- No validated animal model for efficacy testing that fully replicated human disease
Early candidates in the 1990s and 2000s used DNA vaccination, virus-like particles (VLPs), and viral vector approaches — all showing promise in non-human primate models but advancing slowly through institutional and funding pipelines.
The Pre-2014 Pipeline: Slow Progress
By 2014, several vaccine candidates were in early-phase trials but none had advanced to Phase 3:
| Candidate | Developer | Approach | Status in 2014 |
|---|---|---|---|
| rVSV-ZEBOV | NewLink/Merck (licensed from PHAC Canada) | Recombinant vesicular stomatitis virus expressing Ebola GP | Phase 1 completed |
| ChAd3-EBO-Z | Oxford/GSK | Chimpanzee adenovirus vector | Phase 1 |
| Ad26/MVA | Janssen | Heterologous prime-boost adenovirus/MVA | Pre-clinical |
| DNA vaccines | USAMRIID/NIH | Plasmid DNA encoding Ebola antigens | Phase 1 |
None were approved. None had Phase 3 efficacy data. None were available for the outbreak that was about to change everything.
2014–2016: The West Africa Epidemic Forces Action
When Ebola spread to Guinea, Sierra Leone, and Liberia in 2014 and ultimately infected 28,616 people and killed 11,310, the global health establishment confronted an uncomfortable truth: there was no approved treatment and no approved vaccine for a disease that had been known for 38 years.
The geopolitical and public health pressure created by the epidemic — including cases imported to the US and Europe — unlocked funding, streamlined regulatory pathways, and created the political will to push vaccine candidates forward at speed.
WHO R&D Blueprint
WHO convened an emergency R&D summit in early 2015 establishing the R&D Blueprint — a framework for accelerated vaccine and treatment development during public health emergencies. Ebola was the first disease it addressed.
Unprecedented Regulatory Speed
Regulators in the US (FDA), EU (EMA), and national agencies agreed to:
- Accept immunogenicity data and animal challenge studies as primary evidence if human efficacy data could not be generated
- Expedite review processes
- Consider emergency use pathways
rVSV-ZEBOV: From Storage to Trial in Months
The rVSV-ZEBOV vaccine had been sitting in a Health Canada (Public Health Agency of Canada) freezer since 2010, developed using government funding but never commercialised. In 2014, NewLink Genetics (holding the commercial licence) was approached and subsequently licensed the vaccine to Merck.
The Ebola Ça Suffit Trial (Guinea, 2015)
A ring vaccination trial was launched in Guinea in March 2015 — just months after the vaccine’s commercial licensing. The trial was conducted under conditions of active outbreak, requiring:
- Real-time contact tracing to identify vaccination rings
- Community consent in areas with high distrust
- Ultra-cold chain logistics in tropical conditions
Results (published The Lancet, 2017):
- Immediate vaccination arm: 0 cases among 2,108 vaccinees (beyond the 10-day post-vaccination window)
- Delayed arm: 16 cases
- Estimated efficacy: 100% (95% CI: 63.5–100%)
The trial was stopped early on efficacy grounds. The result was transformative.
WHO Emergency Use Listing and DRC 2018
Based on the Guinea trial and Phase 1/2 data, WHO approved rVSV-ZEBOV for Emergency Use Listing (EUL) in 2019, and the vaccine was deployed in the DRC Kivu 2018–2020 outbreak under a ring vaccination compassionate use protocol before its formal FDA/EMA approval.
Over 303,000 doses were administered in DRC before the vaccine received formal regulatory approval.
FDA and EMA Approval (2019–2020)
- EMA: Approved Ervebo (rVSV-ZEBOV) on November 11, 2019 — the first approved Ebola vaccine
- FDA: Approved Ervebo on December 19, 2019
- WHO Prequalification: January 14, 2020
The Johnson & Johnson Two-Dose Regimen
While Merck’s single-dose rVSV-ZEBOV vaccine addressed emergency ring vaccination, a different approach was being developed for prophylactic protection — vaccinating populations before an outbreak occurs.
Janssen (Johnson & Johnson) developed a two-dose heterologous prime-boost regimen:
- Dose 1: Ad26.ZEBOV (adenovirus type 26 vector)
- Dose 2 (56 days later): MVA-BN-Filo (modified vaccinia Ankara expressing multiple filovirus antigens)
This regimen produces sustained immunity expected to last years — appropriate for frontline healthcare workers in endemic areas rather than emergency ring vaccination.
Regulatory approvals:
- EMA: July 2020 (as Zabdeno + Mvabea)
- Currently not FDA-approved but available in Africa under WHO Emergency Use
EBOVAC Africa Trial
A large Phase 3 trial (EBOVAC Africa — Sierra Leone, Liberia, Uganda, Kenya, Côte d’Ivoire) enrolled 23,000+ participants to evaluate long-term immunogenicity. Results confirmed durable antibody responses lasting at least 24 months.
Current Approved Vaccines
As of 2026, two vaccines are approved:
| Vaccine | Product Name | Doses | Approved By | Best Used For |
|---|---|---|---|---|
| rVSV-ZEBOV | Ervebo | Single | FDA, EMA | Emergency ring vaccination |
| Ad26.ZEBOV/MVA | Zabdeno + Mvabea | Two (56 days apart) | EMA | Pre-exposure in healthcare workers |
Both protect only against Zaire ebolavirus. Neither protects against Sudan, Bundibugyo, or other species.
The Remaining Gap: Sudan and Pan-Ebolavirus Vaccines
The 2022 Uganda Sudan ebolavirus outbreak exposed the critical gap: no approved vaccine for Sudan strain. As of 2026:
- ChAd3-Sudan (Oxford/IAVI): In Phase 2 trials
- CEPI funding: Over $200M committed to Sudan ebolavirus vaccine development
- Pan-ebolavirus approaches: Research into vaccines targeting conserved GP epitopes across all species — not yet in human trials
The trajectory is more promising than at any point in history, but another outbreak of Sudan strain or Bundibugyo would still face 2025 responders with no approved vaccine.
Lessons From 40 Years of Development
The Ebola vaccine story illustrates systemic problems in pandemic preparedness financing:
- Market failure is real: Without public funding and advance purchase guarantees, vaccines for epidemic diseases don’t get developed
- Speed is possible: When political will and funding align, vaccine development can move from Phase 1 to approval in under 5 years
- Emergency research is ethical: The Guinea ring trial proved that randomised trials can be conducted during active outbreaks without compromising ethics
- Strain diversity matters: A vaccine portfolio must cover multiple species, not just the most common one